A5077127919- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Long-Term Effects of COVID-19
- Mosquito-borne diseases and control
- HIV, Drug Use, Sexual Risk
- Pneumocystis jirovecii pneumonia detection and treatment
- HIV-related health complications and treatments
- HIV/AIDS Research and Interventions
- Pneumonia and Respiratory Infections
- Nosocomial Infections in ICU
- Autoimmune and Inflammatory Disorders Research
- Immunodeficiency and Autoimmune Disorders
- COVID-19 and healthcare impacts
- Inflammatory Bowel Disease
- HIV/AIDS drug development and treatment
- Vitamin C and Antioxidants Research
- Tuberculosis Research and Epidemiology
- Sex work and related issues
- Antibiotic Use and Resistance
Hospital Universitari Germans Trias i Pujol
2020-2023
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
2023
Universitat de Barcelona
2022
Universitat Autònoma de Barcelona
2020
Universitat de Vic - Universitat Central de Catalunya
2020
No effective treatments for coronavirus disease 2019 (COVID-19) exist. We aimed to determine whether early treatment with hydroxychloroquine (HCQ) would be efficacious outpatients COVID-19.Multicenter open-label, randomized, controlled trial conducted in Catalonia, Spain, between 17 March and 26 May 2020. Patients recently diagnosed <5-day of symptom onset were assigned receive HCQ (800 mg on day 1 followed by 400 once daily 6 days) or usual care. Outcomes reduction viral load nasopharyngeal...
BackgroundCurrent strategies for preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are limited to nonpharmacologic interventions. Hydroxychloroquine has been proposed as a postexposure therapy prevent disease 2019 (Covid-19), but definitive evidence is lacking.MethodsWe conducted an open-label, cluster-randomized trial involving asymptomatic contacts of patients with polymerase-chain-reaction (PCR)–confirmed Covid-19 in Catalonia, Spain. We randomly assigned...
There is an urgent need to identify therapeutics for the treatment of Coronavirus disease 2019 (COVID-19). Although different antivirals are given clinical management SARS-CoV-2 infection, their efficacy still under evaluation. Here, we have screened existing drugs approved human use in a variety diseases, compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication vitro. Among potential 72 tested herein that were previously proposed inhibit only 18 % had IC 50...
ABSTRACT Background Current strategies for preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are limited to non-pharmacological interventions. Hydroxychloroquine (HCQ) has been proposed as a postexposure therapy prevent Coronavirus disease 2019 (Covid-19) but definitive evidence is lacking. Methods We conducted an open-label, cluster-randomized trial including asymptomatic contacts exposed PCR-positive Covid-19 case in Catalonia, Spain. Clusters were...
The outbreak of COVID19 evolved rapidly into a global pandemic, forcing hospitals, including inflammatory bowel disease (IBD) referral units, to change their practices ensure quality care.To describe the clinical outcomes and fulfilment treatment schedule patients with IBD treated biological agents in single-center red-zone report patients' perceptions about COVID-19 measures adopted at our center.Therapeutic adherence were collected for all undergoing intravenous biologicals subcutaneous...
Pre-Exposure Prophylaxis (PrEP) for HIV prevention has been implemented in several countries. Previous literature shown that its cost-effectiveness (and, under some specifications, cost-saving character) is dependent on the reduction price due to generics, time-horizon and effectiveness. The intervention never studied Catalonia after approval of PrEP, a territory with extensive implementation.Economic evaluation implementation pre-exposition prophylaxis using administrative data from Men who...
The duration and regimen of tuberculosis (TB) treatment is currently based predominantly on whether the M. (Mtb) strain drug-sensitive (DS) or multidrug-resistant (MDR) with doses adjusted by patients' weight only. systematic stratification patients for personalized does not exist TB. As each TB case different, individualized regimens should be applied to obtain better outcomes. In this scenario, novel therapeutic approaches are urgently needed (1) improve outcomes (2) shorten duration,...
ABSTRACT There is an urgent need to identify therapeutics for the treatment of Coronavirus diseases 2019 (COVID-19). Although different antivirals are given clinical management SARS-CoV-2 infection, their efficacy still under evaluation. Here, we have screened existing drugs approved human use in a variety diseases, compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication vitro. Among potential 72 tested herein that were previously proposed inhibit only 18% had...
Background: No therapeutics have yet been proven effective for the treatment of mild-illness caused by SARS-CoV-2. We assessed efficacy and safety hydroxychloroquine (HCQ) alone or in combination with cobicistat-boosted darunavir (DRVc) treating patients mild Covid-19. Methods: conducted a randomized, prospective, controlled, open-label trial three health regions Catalonia. After confirmation case Covid-19 disease, we enumerated on list ring all their contacts randomly assigned to either...
Biologics are recommended to treat paediatric ulcerative colitis (UC) that is chronically active or steroid-dependent despite aminosalicylic acids (5-ASA) and thiopurine treatments. Anti-tumour necrosis factor inhibitors (Anti-TNF inhibitors) the agents of choice vedolizumab could be considered as second-line biologic therapy.In current case, we aim describe a successful long-term treatment with in 9-year-old boy severe UC primary non-response infliximab. Concomitant azathioprine was used,...
Nosocomial bloodstream infection (nBSI) is an important clinical concern among COVID-19 hospitalised patients. It can cause sepsis and septic shock leading to high morbidity, mortality, the emergence of antibiotic resistance. The aim this case-control study identify risk factors associated with nBSI development in patients its incidence.A retrospective will be performed. Cases include episodes adult (≥18 years) admitted Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, from...
Introduction: Pre-Exposure Prophylaxis (PrEP) for HIV prevention has been implemented in several countries. Previous literature shown that its cost-effectiveness (and, under some specifications, cost-saving character) is dependent on the reduction price due to generics, time-horizon and effectiveness. The intervention never studied Catalonia, a territory with extensive implementation. Methods: Economic evaluation of implementation pre-exposition prophylaxis using administrative data from Men...